{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:08:20Z","timestamp":1780920500315,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["21153MFDS601"],"award-info":[{"award-number":["21153MFDS601"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2024-00331719 (2024"],"award-info":[{"award-number":["RS-2024-00331719 (2024"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jgo.2025.102779","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:00:38Z","timestamp":1761854438000},"page":"102779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular and cancer-specific mortality in older patients with advanced non-small cell lung cancer following the introduction of immuno-oncology therapies"],"prefix":"10.1016","volume":"17","author":[{"given":"Yeijin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Sun","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanhyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jgo.2025.102779_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.jgo.2025.102779_bb0010","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non\u2013Small Cell Lung Cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2025.102779_bb0020","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-Cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2025.102779_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069008","article-title":"Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study","volume":"376","author":"Potter","year":"2022","journal-title":"Bmj"},{"issue":"8","key":"10.1016\/j.jgo.2025.102779_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0798","article-title":"Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials","volume":"4","author":"O\u2019Connor","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jgo.2025.102779_bb0035","series-title":"American Cancer Society","author":"Cancer Facts & Figures 2024","year":"2024"},{"issue":"10","key":"10.1016\/j.jgo.2025.102779_bb0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.21037\/atm-22-4218","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review","volume":"11","author":"Olivares-Hern\u00e1ndez","year":"2023","journal-title":"Ann Transl Med"},{"issue":"8","key":"10.1016\/j.jgo.2025.102779_bb0045","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2025.102779_bb0050","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2017.35.15_suppl.10009","article-title":"FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. Food and Drug Administration","volume":"35","author":"Singh","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2025.102779_bb0055","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.21037\/tlcr-20-1239","article-title":"Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review","volume":"10","author":"Naltet","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jgo.2025.102779_bb0060","doi-asserted-by":"crossref","first-page":"1058819","DOI":"10.3389\/fimmu.2022.1058819","article-title":"Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"issue":"48","key":"10.1016\/j.jgo.2025.102779_bb0065","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jgo.2025.102779_bb0070","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2021.02.025","article-title":"Cardiovascular disease-specific mortality in 270,618 patients with non-small cell lung cancer","volume":"330","author":"Sun","year":"2021","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.jgo.2025.102779_bb0075","doi-asserted-by":"crossref","first-page":"842","DOI":"10.21037\/tcr-20-2981","article-title":"The risks and trends of cardiac-specific mortality associated with chemotherapy or radiotherapy in a large cohort of non-elderly patients with non-small cell lung cancer","volume":"10","author":"Jiang","year":"2021","journal-title":"Transl Cancer Res"},{"issue":"2","key":"10.1016\/j.jgo.2025.102779_bb0080","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cam4.4948","article-title":"Dual effect of radiotherapy related concomitant cardiovascular diseases in non-small cell lung cancer","volume":"12","author":"Mo","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jgo.2025.102779_bb0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12885-022-09342-5","article-title":"Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis","volume":"22","author":"Carroll","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jgo.2025.102779_bb0090","article-title":"Causes of death and conditional survival estimates of long-term lung cancer survivors","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jgo.2025.102779_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101192","article-title":"Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an international experts panel meeting by the Italian Association of Thoracic Oncology (AIOT)","volume":"8","author":"Gridelli","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.jgo.2025.102779_bb0100","author":"National Cancer Institute Surveillance, E., and End Results Program"},{"issue":"8","key":"10.1016\/j.jgo.2025.102779_bb0105","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.jgo.2025.102779_bb0110","series-title":"SEER-Medicare: Medicare Enrollment, Claims, and Assessment Data","volume":"30 Apr","author":"Sciences, N.C.I.D.o.C.C.P","year":"2021"},{"issue":"5","key":"10.1016\/j.jgo.2025.102779_bb0120","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung Cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.jgo.2025.102779_bb0125","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-22-3699","article-title":"FDA approval summary: atezolizumab as adjuvant treatment following surgical resection and platinum-based chemotherapy for stage II to IIIA NSCLC","volume":"29","author":"Mathieu","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jgo.2025.102779_bb0130","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung Cancer: first-line therapy and beyond","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.jgo.2025.102779_bb0135","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"20","key":"10.1016\/j.jgo.2025.102779_bb0140","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1002\/cncr.25242","article-title":"Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the medicare population","volume":"116","author":"Fairfield","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2025.102779_bb0145","author":"Organization, W.H"},{"issue":"5","key":"10.1016\/j.jgo.2025.102779_bb0150","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"4","key":"10.1016\/j.jgo.2025.102779_bb0155","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/2530374","article-title":"The analysis of failure times in the presence of competing risks","volume":"34","author":"Prentice","year":"1978","journal-title":"Biometrics"},{"issue":"446","key":"10.1016\/j.jgo.2025.102779_bb0160","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.jgo.2025.102779_bb0165","first-page":"e002661","article-title":"Cancer Therapy\u2013Related Cardiac Dysfunction and Heart Failure. Circulation","volume":"9","author":"Bloom","year":"2016","journal-title":"Heart Failure"},{"issue":"5","key":"10.1016\/j.jgo.2025.102779_bb0170","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/annonc\/mdv061","article-title":"Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis","volume":"26","author":"Janssen-Heijnen","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2025.102779_bb0175","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ijc.10882","article-title":"Impact of comorbidity on lung cancer survival","volume":"103","author":"Tammemagi","year":"2003","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2025.102779_bb0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00408-014-9675-5","article-title":"The effect of different comorbidities on survival of non-small cells lung Cancer patients","volume":"193","author":"Iachina","year":"2015","journal-title":"Lung"},{"issue":"7","key":"10.1016\/j.jgo.2025.102779_bb0185","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/thx.2003.018044","article-title":"Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer","volume":"59","author":"Janssen-Heijnen","year":"2004","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jgo.2025.102779_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019661","article-title":"Association of chronic kidney disease with mortality risk in patients with lung cancer: a nationwide Taiwan population-based cohort study","volume":"8","author":"Wei","year":"2018","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.jgo.2025.102779_bb0195","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.athoracsur.2016.04.058","article-title":"Surgical Management of Advanced non-Small Cell Lung Cancer is Decreasing but is Associated with Improved Survival","volume":"102","author":"David","year":"2016","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.jgo.2025.102779_bb0200","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S1010-7940(99)00006-8","article-title":"Perioperative mortality and major cardio-pulmonary complications after lung surgery for non-small cell carcinoma1","volume":"15","author":"Licker","year":"1999","journal-title":"Eur J Cardiothorac Surg"},{"issue":"6","key":"10.1016\/j.jgo.2025.102779_bb0205","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s00595-014-1032-z","article-title":"Impact of cardiopulmonary complications of lung cancer surgery on long-term outcomes","volume":"45","author":"Nojiri","year":"2015","journal-title":"Surg Today"},{"issue":"6","key":"10.1016\/j.jgo.2025.102779_bb0210","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jtcvs.2011.09.072","article-title":"Surgical treatment of lung cancer: predicting postoperative morbidity in the elderly population","volume":"143","author":"Rueth","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.jgo.2025.102779_bb0215","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaccao.2022.10.013","article-title":"Racial and ethnic disparities in all-cause and cardiovascular mortality among Cancer patients in the U.S","volume":"5","author":"Zhu","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"55","key":"10.1016\/j.jgo.2025.102779_bb0220","first-page":"3","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"JNCI Monographs"},{"issue":"6","key":"10.1016\/j.jgo.2025.102779_bb0225","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jclinepi.2012.09.017","article-title":"A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions","volume":"66","author":"Latouche","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jgo.2025.102779_bb0235","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MLR.0000000000001974","article-title":"Accuracy of Cancer registry primary payer information and implications for policy research","volume":"62","author":"Davidoff","year":"2024","journal-title":"Med Care"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825005958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825005958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:34:41Z","timestamp":1780918481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406825005958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1879406825005958"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102779","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and cancer-specific mortality in older patients with advanced non-small cell lung cancer following the introduction of immuno-oncology therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102779"}}